EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieMultizentrische StudieOpen access · CC BY-NC 4.0

Short‐course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy

P J de Kam iD, S Zielen, J A Bernstein iD, U Berger iD, M Berger iD, M Cuevas, D Cypcar, A Fuhr-Horst, W A Greisner, M Jandl, S Laßmann, M Worm iD and 16 more

Allergy · 2023

DOI: 10.1111/all.15788 ↗

At a glance

Randomisierte kontrollierte Studie in Allergy, 2023. Written by P J de Kam and 27 co-authors. Institution: Allergy Therapeutics PLC, Worthing, UK. Major MEDLINE topics: Poaceae, Rhinitis, Allergic, Seasonal, Desensitization, Immunologic, Allergens. Cited 25 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Allergy Therapeutics.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

A modified grass allergen subcutaneous immunotherapy (SCIT) product with MicroCrystalline Tyrosine and monophosphoryl lipid‐A as an adjuvant system (Grass MATA MPL [PQ Grass]) is being developed as short‐course treatment of grass‐pollen allergic rhinitis (SAR) and/or rhinoconjunctivitis. We sought to evaluate the combined symptom and medication score (CSMS) of the optimized cumulative dose of 27,600 standardized units (SU) PQ Grass in a field setting prior to embarking on a pivotal Phase III trial.

Methods

In this exploratory, randomized, double‐blind, placebo‐controlled trial subjects were enrolled across 14 sites (Germany and the United States of America). Six pre‐seasonal subcutaneous injections of PQ Grass (using conventional or extended regimens) or placebo were administered to 119 subjects (aged 18–65 years) with moderate‐to‐severe SAR with or without asthma that was well‐controlled. The primary efficacy endpoint was CSMS during peak grass pollen season (GPS). Secondary endpoints included Rhinoconjunctivitis Quality of Life Questionnaire standardized (RQLQ‐S) and allergen‐specific IgG4 response.

Results

The mean CSMS compared to placebo was 33.1% ( p = .0325) and 39.5% ( p = .0112) for the conventional and extended regimens, respectively. An increase in IgG4 was shown for both regimens ( p < .01) as well as an improvement in total RQLQ‐S for the extended regimen (mean change −0.72, p = .02). Both regimens were well‐tolerated.

Conclusions

This trial demonstrated a clinically relevant and statistically significant efficacy response to PQ Grass. Unprecedented effect sizes were reached for grass allergy of up to ≈40% compared to placebo for CSMS after only six PQ Grass injections. Both PQ Grass regimens were considered equally safe and well‐tolerated. Based on enhanced efficacy profile extended regime will be progressed to the pivotal Phase III trial.

Subjects

MeSH terms (MEDLINE)

PoaceaeRhinitis, Allergic, SeasonalDesensitization, ImmunologicAllergensHumansAdultMaleFemaleMiddle AgedYoung AdultTreatment OutcomeInjections, SubcutaneousAdolescentAgedDouble-Blind MethodQuality of Life

Author keywords

allergic rhinoconjunctivitisgrass pollen allergyshort-course treatmentsubcutaneous immunotherapy

Substances

Allergens

Authors and institutions

  • Allergy Therapeutics PLC, Worthing, UK.
  • Children and Adolescents Department, Allergology, Pulmonology & Cystic Fibrosis, Goethe University, Frankfurt, Germany.
  • Bernstein Clinical Research Center, LLC, Cincinnati, Ohio, USA.
  • Aerobiology and Pollen Research Unit, Department of Oto-Rhino-Laryngology, Medical University Vienna, Vienna, Austria.
  • Department of Otorhinolaryngology, Wiener Gesundheitsverbund, Hospital Hietzing, Vienna, Austria.
  • Clinic and Polyclinic of Otorhinolaryngology, University Clinic Carl Gustav Carus, Dresden, Germany.

ORCID profiles: P J de Kam, J A Bernstein, U Berger, M Berger, M Worm, J Matz, E Sher, R Mösges, M H Shamji, L DuBuske, K Oluwayi, M D Heath, M F Kramer, M A Skinner

Funding

  • Allergy Therapeutics

Cite

APA

de Kam, P. J., Zielen, S., Bernstein, J. A., Berger, U., Berger, M., Cuevas, M., Cypcar, D., Fuhr-Horst, A., Greisner, W. A., Jandl, M., Laßmann, S., Worm, M., Matz, J., Sher, E., Smith, C., Steven, G. C., Mösges, R., Shamji, M. H., DuBuske, L., …, & Skinner, M. A. (2023). Short‐course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy. Allergy. https://doi.org/10.1111/all.15788

Vancouver

de Kam PJ, Zielen S, Bernstein JA, Berger U, Berger M, Cuevas M, et al. Short‐course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy. Allergy. 2023. doi:10.1111/all.15788

BibTeX
@article{deKam2023,
  author = {de Kam, P J and Zielen, S and Bernstein, J A and Berger, U and Berger, M and Cuevas, M and Cypcar, D and Fuhr-Horst, A and Greisner, W A and Jandl, M and Laßmann, S and Worm, M and Matz, J and Sher, E and Smith, C and Steven, G C and Mösges, R and Shamji, M H and DuBuske, L and Borghese, F and Oluwayi, K and Zwingers, T and Seybold, M and Armfield, O and Heath, M D and Hewings, S J and Kramer, M F and Skinner, M A},
  title = {Short‐course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy},
  journal = {Allergy},
  year = {2023},
  doi = {10.1111/all.15788}
}
Start for free →